IBCSG 11-93

  • Ovarian ablation followed by tamoxifen with or without 4 cycles of AC as adjuvant therapy for premenopausal women, node positive, hormone receptor positive breast cancer patients who are suitable for endocrine therapy alone.

  • Study Chairs
    Prof. Beat Thürlimann - St. Gallen, Switzerland
    Prof. Monica Castiglione - Bern, Switzerland

    Statistician
    Karen Price

    Director of the Data Management Center
    Holly Shaw

    IBCSG Data Management Center/FSTRF
    4033 Maple Road
    Amherst, New York 14226 USA
    Phone: +1 716 834 0900
    Fax: +1 716 833 3990
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

    Date of Activation
    May 1, 1993

    Date of Closure
    November 1, 1998

    Targeted Accrual
    400 patients

    Final Accrual
    174 patients

    Date of Discontinued Follow-up
    December 31, 2011

ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: contact@etop.ibcsg.org

Member Login